Risankizumab in CD: Outcomes Remain Stable up to 3 Years Risankizumab in CD: Outcomes Remain Stable up to 3 Years
Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn ' s disease, according to a new study.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology Source Type: news
More News: Crohn's Disease | Drugs & Pharmacology | Gastroenterology | Inflammatory Bowel Disease | Study